Advancing Nutritional Science for Children With Functional Dyspepsia

March 6, 2022 updated by: Bruno Chumpitazi, Baylor College of Medicine
This study evaluates four different meals and how they induce gastrointestinal symptoms in children with functional dyspepsia. All subjects will receive each meal and rate their gastrointestinal symptoms during each meal.

Study Overview

Status

Completed

Conditions

Intervention / Treatment

Detailed Description

Food can often exacerbate gastrointestinal symptoms in adults and children with functional dyspepsia. However, it is unclear which foods exacerbate symptoms more than others.

Children with post-prandial distress functional dyspepsia will receive four different meals with variables being: semi-solid vs. solid and high fat vs high carbohydrate. At the time of ingestion and for up to 3 hours after each meal, subjects will rate their gastrointestinal symptoms. Comparisons of symptom onset and severity will be made for each meal.

Enrolled subjects will have undergone previous gastrointestinal evaluations: gastric emptying study and/or upper endoscopy. In addition, subjects will complete psychosocial measures: Behavioral Assessment for Children-3, childhood somatization inventory.

The first goal is to compare the severity of gastrointestinal symptoms with different composition and consistency meals. The second goal is to correlate the severity of postprandial gastrointestinal symptoms to psychosocial distress, gastric neuromotor function (emptying and accommodation), and duodenal inflammation.

Study Type

Interventional

Enrollment (Actual)

40

Phase

  • Not Applicable

Contacts and Locations

This section provides the contact details for those conducting the study, and information on where this study is being conducted.

Study Locations

    • Texas
      • Houston, Texas, United States, 77030
        • Children's Nutrition Research Center

Participation Criteria

Researchers look for people who fit a certain description, called eligibility criteria. Some examples of these criteria are a person's general health condition or prior treatments.

Eligibility Criteria

Ages Eligible for Study

10 years to 17 years (Child)

Accepts Healthy Volunteers

No

Genders Eligible for Study

All

Description

Inclusion Criteria:

  • Rome IV Functional Dyspepsia with post-prandial distress
  • Previously completed normal upper endoscopy with duodenal biopsies and/or previously completed a gastric emptying scintigraphy study

Exclusion Criteria:

  • Previous abdominal surgery
  • Current or previous formal psychiatric diagnosis (e.g. anxiety disorder) requiring therapy or psychotropics
  • Serious chronic medical condition requiring regular medical care
  • Allergy to meal components to be ingested during the study
  • On specialized diet required for a medical condition
  • Pregnancy
  • Inability to eat by mouth

Study Plan

This section provides details of the study plan, including how the study is designed and what the study is measuring.

How is the study designed?

Design Details

  • Primary Purpose: Other
  • Allocation: Randomized
  • Interventional Model: Crossover Assignment
  • Masking: Double

Arms and Interventions

Participant Group / Arm
Intervention / Treatment
Active Comparator: High fat/ Semi-solid
Subject will receive a high fat/semi-solid meal.
Meals composed of either high fat vs. high carbohydrate and semi-solid vs. solid
Active Comparator: High carbohydrate/ Semi-solid
Subject will receive a high carbohydrate/semi-solid meal.
Meals composed of either high fat vs. high carbohydrate and semi-solid vs. solid
Active Comparator: High fat/ solid
Subject will receive a high fat/solid meal.
Meals composed of either high fat vs. high carbohydrate and semi-solid vs. solid
Active Comparator: High carbohydrate/ solid
Subject will receive a high carbohydrate/solid meal.
Meals composed of either high fat vs. high carbohydrate and semi-solid vs. solid

What is the study measuring?

Primary Outcome Measures

Outcome Measure
Measure Description
Time Frame
Dyspepsia Symptom Severity
Time Frame: up to 16 weeks
Change from baseline gastrointestinal symptoms using total visual analogue scale score
up to 16 weeks

Secondary Outcome Measures

Outcome Measure
Measure Description
Time Frame
Dyspepsia Symptom Onset
Time Frame: up to 16 weeks
Time to maximum symptom severity
up to 16 weeks
Duodenal inflammation
Time Frame: up to 16 weeks
Previously obtained duodenal mucosal biopsies will be re-evaluated for eosinophils and mast cells
up to 16 weeks
Gastric retention
Time Frame: up to 16 weeks
Gastric retention values will be captured from a previously completed 4-hour gastric emptying scintigraphy study
up to 16 weeks
Psychosocial distress
Time Frame: up to 16 weeks
Anxiety, Depression, and Somatization will be determined using Behavioral Assessment for Children-3 (t-scores for anxiety and depression) and Children's Somatization Inventory Score (total score).
up to 16 weeks
Gastric accommodation
Time Frame: up to 16 weeks
Gastric accommodation will be determined from a previously completed 4-hour gastric scintigraphy study using analysis of the time zero image.
up to 16 weeks

Collaborators and Investigators

This is where you will find people and organizations involved with this study.

Collaborators

Investigators

  • Principal Investigator: Bruno Chumpitazi, MD, Baylor College Of Medicine

Study record dates

These dates track the progress of study record and summary results submissions to ClinicalTrials.gov. Study records and reported results are reviewed by the National Library of Medicine (NLM) to make sure they meet specific quality control standards before being posted on the public website.

Study Major Dates

Study Start (Actual)

August 1, 2019

Primary Completion (Actual)

December 1, 2021

Study Completion (Actual)

December 1, 2021

Study Registration Dates

First Submitted

May 3, 2019

First Submitted That Met QC Criteria

August 9, 2019

First Posted (Actual)

August 12, 2019

Study Record Updates

Last Update Posted (Actual)

March 8, 2022

Last Update Submitted That Met QC Criteria

March 6, 2022

Last Verified

March 1, 2022

More Information

Terms related to this study

Additional Relevant MeSH Terms

Other Study ID Numbers

  • H-44307

Plan for Individual participant data (IPD)

Plan to Share Individual Participant Data (IPD)?

No

Drug and device information, study documents

Studies a U.S. FDA-regulated drug product

No

Studies a U.S. FDA-regulated device product

No

This information was retrieved directly from the website clinicaltrials.gov without any changes. If you have any requests to change, remove or update your study details, please contact register@clinicaltrials.gov. As soon as a change is implemented on clinicaltrials.gov, this will be updated automatically on our website as well.

Clinical Trials on Dyspepsia

Clinical Trials on Diet

3
Subscribe